CytoDyn Inc CYDY

Healthcare Biotechnology

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. The Company is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions. Its core areas of clinical development are human immunodeficiency viruses (HIV), non-alcoholic steatohepatitis (NASH), and solid tumors in oncology. The areas of clinical focus in HIV are the lifting of the clinical hold, creation of a long-acting formulation of leronlimab and an HIV functional cure in using adenovirus vectors (AAV). In NASH, its focus is on the general population of those affected by NASH, and the subpopulation of patients with NASH and HIV. Regarding oncology, its focus remains on combination therapy for solid tumors.

OTCQB:CYDY - Post by User

CytoDyn Inc > Patent movement

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Dec 23, 2022 1:47am

122 Views

Post# 35188843

RE:Patent movement

The USPTO has been busy - there is also some movement on a second patent application.
I have read the Examiners document but don't understand it and bottom line it is being turned back to the inventor to reconstruct the submission under what they refer to as a restriction/election requirement.

17/148,281 | 230042.431:

CCR5 BINDING AGENT FOR THE TREATMENT OF CCR5 POSITIVE METASTATIC CANCER

Documents & transaction history

12/15/2022	Email Notification
12/15/2022	Mail Restriction Requirement
12/11/2022	Restriction/Election Requirement
07/17/2022	Case Docketed to Examiner in GAU